Thursday, 15 October 2026European Markets

GC RIEBER SHIPPING Stock Bullish By 20% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of GC RIEBER SHIPPING (Oslo Børs Benchmark Index_GI: RISH.OL) rose by a staggering 20.88% in 10 sessions from kr14.85 to kr17.95 at 14:37 EST on Friday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is falling 0.85% to kr1,197.85, after two successive sessions in a row of losses.

GC RIEBER SHIPPING's last close was kr17.95, 6.75% below its 52-week high of kr19.25.

About GC RIEBER SHIPPING

GC Rieber Shipping ASA operates as a ship-owning project house with a focus on developing maritime projects in Norway and internationally. The company was incorporated in 2005 and is headquartered in Bergen, Norway. GC Rieber Shipping ASA is a subsidiary of GC Rieber AS.

Earnings Per Share

As for profitability, GC RIEBER SHIPPING has a trailing twelve months EPS of kr-0.41.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.94%.

Moving Average

GC RIEBER SHIPPING's value is way above its 50-day moving average of kr15.23 and way above its 200-day moving average of kr12.49.

Earnings Before Interest, Taxes, Depreciation, and Amortization

GC RIEBER SHIPPING's EBITDA is -4.32.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Apr 26, 2023, the estimated forward annual dividend rate is 0.25 and the estimated forward annual dividend yield is 1.41%.

More news about GC RIEBER SHIPPING (RISH.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com